Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024

PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024

Technavio has been monitoring the parp (Poly ADP-ribose Polymerase) inhibitors market and it is poised to grow by $ 810.23 million during 2020-2024 progressing at a CAGR of 12% during the forecast period. Our reports on parp (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors and increasing patient assistance programs. In addition, expanded application of PARP inhibitors is anticipated to boost the growth of the market as well.

The parp (Poly ADP-ribose Polymerase) inhibitors market analysis includes end-user segment and geographic landscapes

Technavio's parp (Poly ADP-ribose Polymerase) inhibitors market is segmented as below:

By End-User

  • Ovarian cancer
  • Breast cancer
  • Others
By Geographic Landscapes
  • North America
  • Europe
  • APAC
  • South America
  • MEA
This study identifies the ease of administration as one of the prime reasons driving the parp (Poly ADP-ribose Polymerase) inhibitors market growth during the next few years.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our parp (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:
  • Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
  • Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
  • Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis
"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-ribose Polymerase) inhibitors market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the parp (Poly ADP-ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.


  • Executive Summary
  • Market Landscape
    • Market ecosystem
      • Table Parent market
    • Market characteristics
      • Table Market characteristics
    • Value chain analysis
      • Table Value chain analysis: Pharamaceuticals
      • Research and development (R&D) and drug discovery
      • Integration and product development
      • Manufacturing
      • Outbound logistics
      • Marketing and sales
      • Support services
      • Innovation
  • Market Sizing
    • Market definition
      • Table Offerings of vendors included in the market definition
    • Market size 2019
    • Market segment analysis
      • Table Market segments
    • Market outlook: Forecast for 2019 - 2024
      • Table Global - Market size and forecast 2019-2024 ($ millions)
      • Table Global - Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table Global market: Year-over-year growth 2019-2024 (%)
  • Five Forces Analysis
    • Five forces summary
      • Table Five forces analysis 2019 and 2024
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2019
  • Market Segmentation by End-user
    • Market segments
      • Table End-user - Market share 2019-2024 (%)
    • Comparison by End-user
      • Table Comparison by End-user
    • Ovarian cancer - Market size and forecast 2019- 2024
      • Table Ovarian cancer - Market size and forecast 2019-2024 ($ millions)
      • Table Ovarian cancer- Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table Ovarian cancer - Year-over-year growth 2019-2024 (%)
    • Breast cancer - Market size and forecast 2019- 2024
      • Table Breast cancer - Market size and forecast 2019-2024 ($ millions)
      • Table Breast cancer- Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table Breast cancer - Year-over-year growth 2019-2024 (%)
    • Others - Market size and forecast 2019-2024
      • Table Others - Market size and forecast 2019-2024 ($ millions)
      • Table Others- Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table Others - Year-over-year growth 2019-2024 (%)
    • Market opportunity by End user
      • Table Market opportunity by End user
  • Customer landscape
    • Table Customer landscape
  • Geographic Landscape
    • Geographic segmentation
      • Table Market share by geography 2019-2024 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2019- 2024
      • Table North America - Market size and forecast 2019-2024 ($ millions)
      • Table North America - Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table North America - Year-over-year growth 2019-2024 (%)
    • Europe - Market size and forecast 2019-2024
      • Table Europe - Market size and forecast 2019-2024 ($ millions)
      • Table Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table Europe - Year-over-year growth 2019-2024 (%)
    • APAC - Market size and forecast 2019-2024
      • Table APAC - Market size and forecast 2019-2024 ($ millions)
      • Table APAC - Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table APAC - Year-over-year growth 2019-2024 (%)
    • South America - Market size and forecast 2019- 2024
      • Table South America - Market size and forecast 2019-2024 ($ millions)
      • Table South America - Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 impact
      • Table South America - Year-over-year growth 2019-2024 (%)
    • MEA - Market size and forecast 2019-2024
      • Table MEA - Market size and forecast 2019-2024 ($ millions)
      • Table MEA - Market size and forecast 2019-2024 ($ millions) exclusive of Covid-19 Impact
      • Table MEA - Year-over-year growth 2019-2024 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity by geography
      • Table Market opportunity by geography ($ millions)
  • Drivers, Challenges, and Trends
    • Market drivers
      • Expanded application of PARP inhibitors
      • Ease of administration
      • Increasing patient assistance programs
    • Market challenges
      • Advent of novel therapies
      • Limitations of PARP inhibitors
      • Trial failures
        • Table Impact of drivers and challenges
    • Market trends
      • Extensive ongoing research
      • Growing prevalence of cancer
      • New research areas
  • Vendor Landscape
    • Overview
      • Competitive Scenario
    • Vendor Landscape
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
      • Table Industry risks
  • Vendor Analysis
    • Vendors covered
      • Table Vendors covered
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. –Overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. –Key news
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Segment focus
    • AstraZeneca Plc
      • Table AstraZeneca Plc – Overview
      • Table AstraZeneca Plc - Business segments
      • Table AstraZeneca Plc- Key news
      • Table AstraZeneca Plc - Key offerings
      • Table AstraZeneca Plc - Segment focus
    • Bayer AG
      • Table Bayer AG – Overview
      • Table Bayer AG - Business segments
      • Table Bayer AG – Key news
      • Table Bayer AG - Key offerings
      • Table Bayer AG - Segment focus
    • Clovis Oncology Inc.
      • Table Clovis Oncology Inc. –Overview
      • Table Clovis Oncology Inc. - Business segments
      • Table Clovis Oncology Inc. –Key news
      • Table Clovis Oncology Inc. - Key offerings
      • Table Clovis Oncology Inc. - Segment focus
    • Daiichi Sankyo Co. Ltd.
      • Table Daiichi Sankyo Co. Ltd. –Overview
      • Table Daiichi Sankyo Co. Ltd. - Business segments
      • Table Daiichi Sankyo Co. Ltd. –Key news
      • Table Daiichi Sankyo Co. Ltd. - Key offerings
      • Table Daiichi Sankyo Co. Ltd. - Segment focus
    • GlaxoSmithKline Plc
      • Table GlaxoSmithKline Plc – Overview
      • Table GlaxoSmithKline Plc - Business segments
      • Table GlaxoSmithKline Plc – Key news
      • Table GlaxoSmithKline Plc - Key offerings
      • Table GlaxoSmithKline Plc - Segment focus
    • Jiangsu Hengrui Medicine Co. Ltd.
      • Table Jiangsu Hengrui Medicine Co. Ltd. –Overview
      • Table Jiangsu Hengrui Medicine Co. Ltd. - Business segments
      • Table Jiangsu Hengrui Medicine Co. Ltd. - Key offerings
      • Table Jiangsu Hengrui Medicine Co. Ltd. - Segment focus
    • Johnson & Johnson
      • Table Johnson & Johnson – Overview
      • Table Johnson & Johnson - Business segments
      • Table Johnson & Johnson - Key offerings
      • Table Johnson & Johnson - Segment focus
    • Pfizer Inc.
      • Table Pfizer Inc. –Overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc.- Key news
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Segment focus
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. –Overview
      • Table Teva Pharmaceutical Industries Ltd. - Business segments
      • Table Teva Pharmaceuticals Industries Ltd. –Key news
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
  • Appendix
    • Scope of the report
      • Definition
      • Objectives
      • Notes and caveats
    • Currency conversion rates for US$
      • Table Currency conversion rates for US$
    • Research methodology
      • Table Research Methodology
      • Table Validation techniques employed for market sizing
      • Table Information sources
    • List of abbreviations
      • Table List of abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook